Ken Rollins

Partner in Charge – San Diego
Full contact info

I am an extension of my clients, serving as an advisor at critical inflection points as my clients grow and succeed.

Passions

Family

Motorcycles

Running

Experience

Design Therapeutics $125 million Series B Financing and $240 million IPO

Cooley advised Design Therapeutics on its $125 million Series B financing and $240 million IPO. Partner Ken Rollins led the Cooley team advising Design Therapeutics, a preclinical-stage biopharmaceutical company.

 

Related contacts

Ken Rollins
Partner in Charge – San Diego, San Diego

Related Practices & Industries

Silverback Therapeutics: $242 million Initial Public Offering

Silverback Therapeutics, a clinical-stage biopharmaceutical company, in its $242 million IPO.

Related contacts

Ken Rollins
Partner in Charge – San Diego, San Diego

Related Practices & Industries

VelosBio Agrees to Sell to Merck for $2.75 Billion

November 9, 2020

Cooley advised VelosBio, a clinical-stage biopharmaceutical company, on its agreement to sell to Merck, through a subsidiary, for $2.75 billion. Cooley lawyers Barbara Borden, Ken Rollins and Rowook Park led the team advising VelosBio on the transaction, which is expected to close by the end of 2020.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Ken Rollins
Partner in Charge – San Diego, San Diego
Rowook Park
Partner, San Diego
Rajdeep Roger Bains
Associate, San Diego
David Burns
Special Counsel, Washington, DC
Ross Eberly
Partner, Santa Monica
Vince Flynn
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
Jeffrey J. Tolin
Partner, New York

Related Practices & Industries

Synthorx: $63 Million Series C Financing

April 30, 2018

Synthorx, a developer of protein therapeutics, in its $63 million Series C financing.

Related contacts

Ken Rollins
Partner in Charge – San Diego, San Diego
Asa Henin
Special Counsel, San Diego

Auspex Pharma Acquired by Teva for $3.5 Billion

March 30, 2015

Cooley advised Auspex Pharmaceuticals, Inc. on its acquisition by Teva Pharmaceutical Industries Ltd. for approximately $3.5 billion. Auspex Pharmaceuticals is a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases.

Read more

Related contacts

Barbara Borden
Partner, San Diego
Ken Rollins
Partner in Charge – San Diego, San Diego
Rama Padmanabhan
Partner, San Diego
Megan Arthur Schilling
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Howard Morse
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Todd Gluth
Partner, San Diego
Matthew D. Silverman
Special Counsel, Santa Monica

Related Practices & Industries

View more

Admissions and credentials

California